Nitrase Therapeutics
Carla Ramos has a diverse work experience spanning several companies in the biotechnology and pharmaceutical industries. Carla is currently serving as the Director of Operations at Nitrase Therapeutics since September 2020. Previously, they worked at iPierian where they held roles as an Associate Scientist from March 2012 onwards and as a Sr. Research Associate from November 2009 to March 2012. Prior to that, Carla worked at Elan Pharmaceuticals as an Associate Scientist from 2007 to 2009 and as a Senior Research Associate from 2003 to 2007. Carla began their career at Genelabs Technologies as a Senior Research Associate from 2000 to 2004.
Carla Ramos obtained their Master's degree in Cell and Molecular Biology from San Francisco State University, where they attended from 1997 to 2000.
This person is not in any teams
Nitrase Therapeutics
1 followers
Nitrase Therapeutics is a pioneering biopharmaceutical company deploying its unique NITROME platform to unlock the therapeutic potential of nitrases, a new class of enzymes that it discovered, to develop a pipeline of therapies against a broad variety of diseases. The medicines that Nitrase Therapeutics is developing will target these enzymes and potentially help slow or halt the progression of a wide variety of diseases in which nitrases and nitro-substrates play a role, including Parkinson’s and cancer. Nitrase Therapeutics (under the former name Nitrome Biosciences) has been widely recognized and has won multiple awards including the prestigious Target Advancement grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF).